<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000662011"><TermName>hLL1</TermName><TermDefinition><DefinitionText>A substance being studied in the treatment of multiple myeloma and several other types of cancer. It binds to CD74, a protein on the surface of myeloma cells and certain other types of cells. It may help kill cancer cells. hLL1 is a type of monoclonal antibody. Also called IMMU-110 and milatuzumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><SpanishTermName>hLL1</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia bajo estudio para el tratamiento del mieloma múltiple y varios tipos de cáncer. Se une a la proteína CD74 en la superficie de las células de mieloma y ciertos tipos de células. Podría ayudar a eliminar las células de cáncer. El hLL1 es un tipo de anticuerpo monoclonal. También se llama IMMU-110 y milatuzumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-04-07</DateFirstPublished></GlossaryTerm>
